Skip to Content

Dyadic International Inc DYAI

Morningstar Rating
$1.76 −0.05 (2.49%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

DYAI is trading at a 881% premium.
Price
$1.75
Fair Value
$7.92
Uncertainty
Extreme
1-Star Price
$68.88
5-Star Price
$8.86
Economic Moat
Fvd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DYAI is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.81
Day Range
$1.661.81
52-Week Range
$1.282.67
Bid/Ask
$1.78 / $1.95
Market Cap
$51.46 Mil
Volume/Avg
77,164 / 89,970

Key Statistics

Price/Earnings (Normalized)
Price/Sales
22.49
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
7

Comparables

Valuation

Metric
DYAI
IMVT
PTGX
Price/Earnings (Normalized)
13.22
Price/Book Value
11.386.443.37
Price/Sales
22.496.15
Price/Cash Flow
10.11
Price/Earnings
DYAI
IMVT
PTGX

Financial Strength

Metric
DYAI
IMVT
PTGX
Quick Ratio
5.4413.1815.61
Current Ratio
5.5413.7015.72
Interest Coverage
Quick Ratio
DYAI
IMVT
PTGX

Profitability

Metric
DYAI
IMVT
PTGX
Return on Assets (Normalized)
−71.01%−44.70%51.28%
Return on Equity (Normalized)
−101.42%−49.06%56.32%
Return on Invested Capital (Normalized)
−91.23%−53.44%51.24%
Return on Assets
DYAI
IMVT
PTGX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
ZxpbjvpjvLkx$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
WfhnwfmPqgqsf$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
VdqscwbLvfyk$116.0 Bil
Moderna Inc
MRNA
DbwzfzncpNznw$51.1 Bil
argenx SE ADR
ARGX
JdlqmkwdkHtddn$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
QcyrrwccvCmxxts$21.0 Bil
BioNTech SE ADR
BNTX
WtmzvjbxFdps$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
MfbwhzkrwBjgkj$15.9 Bil
United Therapeutics Corp
UTHR
BgkqxfgkdMwdh$14.0 Bil
Incyte Corp
INCY
BxtfnrdkwFlkrdr$12.5 Bil

Sponsor Center